Pub Date : 2020-05-01DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7144
M. Sterclova, K. Sikorová, A. Kishore, M. Petrek, M. Vašáková
{"title":"Effect of Genetic Background on Manifestation of Progressive Fibrosing Interstitial Lung Diseases","authors":"M. Sterclova, K. Sikorová, A. Kishore, M. Petrek, M. Vašáková","doi":"10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7144","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7144","url":null,"abstract":"","PeriodicalId":296065,"journal":{"name":"D56. ENVIRONMENTAL INTERSTITIAL LUNG DISEASE","volume":"2014 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121556829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-01DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7142
S. R. Patel, A. Chaudhry, A. Magh, C. Verdick, W. Nasser, Z. Mattar, A. Jani, Ryan Basith Fasih Khan
{"title":"Idiopathic Pulmonary Fibrosis: A Single Center Experience of Ventilator Use, Outcomes and Resource Burden","authors":"S. R. Patel, A. Chaudhry, A. Magh, C. Verdick, W. Nasser, Z. Mattar, A. Jani, Ryan Basith Fasih Khan","doi":"10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7142","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7142","url":null,"abstract":"","PeriodicalId":296065,"journal":{"name":"D56. ENVIRONMENTAL INTERSTITIAL LUNG DISEASE","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117128446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Furusawa, J. Cardwell, T. Okamoto, A. Walts, I. Konigsberg, J. Kurche, T. Bang, M. Schwarz, C. Cool, K. Brown, P. Wolters, Joyce S. Lee, Ivana V. Yang, D. A. Schwartz
Background: Chronic hypersensitivity pneumonitis (CHP) is caused by an immune response to antigen inhalation and is characterized by progressive pulmonary fibrosis. The histopathological and clinical features of CHP are variable, however, a subset of CHP patients have usual interstitial pneumonia and behave clinically similar to patients with idiopathic pulmonary fibrosis (IPF). To determine the common and unique molecular features of CHP and IPF, we conducted a transcriptome analysis of lung samples from CHP (N=82), IPF (N=103), and unaffected controls (N=103). Methods: Gene expression in lung tissue was determined adjusting for sex, race, age, explant site, and smoking history, and using false discovery rate (FDR) to control for multiple comparisons. Findings: When compared to controls, we identified 413 upregulated and 317 downregulated genes in CHP, and 861 upregulated and 322 downregulated genes in IPF. Concordantly up/down-regulated genes in CHP and IPF were related to collagen catabolic processes and epithelial development, whereas genes specific to CHP were related to chemokine-mediated signaling and immune responsiveness. Using weighted gene co-expression network analysis (WGCNA), we found that among subjects with CHP, genes involved in adaptive immunity or epithelial cell development were associated with improved or reduced lung function respectively, and that MUC5B expression was associated with epithelial cell development. MUC5B expression was also associated with lung fibrosis and honeycombing. Interpretation: Gene expression analysis of CHP and IPF identified signatures common to CHP and IPF, as well as genes uniquely expressed in CHP. Select modules of gene expression are characterized by distinct clinical and pathological features of CHP. Funding Statement: NHLBI (R01-HL097163, P01-HL092870, UH3-HL123442, and DoD W81XWH17-1-0597). Declaration of Interests: None of the authors report conflicts of interest relevant to this study. D.A.S. is the founder and chief scientific officer of Eleven P15, a company focused on the early diagnosis and treatment of pulmonary fibrosis. D.A.S. has an awarded patent (US patent no: 8,673,565) for the treatment and diagnosis of fibrotic lung disease. Ethics Approval Statement: This study conformed to the Declaration of Helsinki and was approved by the Colorado Multiple Institution Board (COMIRB) 15-1147.
背景:慢性超敏性肺炎(CHP)是由对抗原吸入的免疫反应引起的,以进行性肺纤维化为特征。CHP的组织病理学和临床特征是多变的,然而,一部分CHP患者有常见的间质性肺炎,其临床表现与特发性肺纤维化(IPF)患者相似。为了确定CHP和IPF的共同和独特的分子特征,我们对CHP (N=82)、IPF (N=103)和未受影响的对照组(N=103)的肺样本进行了转录组分析。方法:调整性别、种族、年龄、外植体位置、吸烟史等因素,测定肺组织中基因表达,并采用错误发现率(FDR)进行多重比较控制。结果:与对照组相比,我们在CHP中发现了413个上调基因和317个下调基因,在IPF中发现了861个上调基因和322个下调基因。CHP和IPF中一致上调/下调的基因与胶原分解代谢过程和上皮发育有关,而CHP特异性基因与趋化因子介导的信号传导和免疫反应有关。通过加权基因共表达网络分析(WGCNA),我们发现在CHP受试者中,参与适应性免疫或上皮细胞发育的基因分别与肺功能改善或降低相关,MUC5B表达与上皮细胞发育相关。MUC5B的表达也与肺纤维化和蜂窝化有关。解释:CHP和IPF的基因表达分析发现了CHP和IPF的共同特征,以及CHP中独特表达的基因。所选择的基因表达模块具有CHP独特的临床和病理特征。资助声明:NHLBI (R01-HL097163, P01-HL092870, UH3-HL123442, DoD W81XWH17-1-0597)。利益声明:没有作者报告与本研究相关的利益冲突。D.A.S.是Eleven P15的创始人兼首席科学官,该公司专注于肺纤维化的早期诊断和治疗。D.A.S.拥有一项用于治疗和诊断纤维化肺疾病的专利(美国专利号:8,673,565)。伦理批准声明:本研究符合赫尔辛基宣言,并已获得科罗拉多州多机构委员会(COMIRB) 15-1147的批准。
{"title":"Chronic Hypersensitivity Pneumonitis (CHP), an Interstitial Lung Disease (ILD) with Distinct Molecular Signatures","authors":"H. Furusawa, J. Cardwell, T. Okamoto, A. Walts, I. Konigsberg, J. Kurche, T. Bang, M. Schwarz, C. Cool, K. Brown, P. Wolters, Joyce S. Lee, Ivana V. Yang, D. A. Schwartz","doi":"10.2139/ssrn.3514777","DOIUrl":"https://doi.org/10.2139/ssrn.3514777","url":null,"abstract":"Background: Chronic hypersensitivity pneumonitis (CHP) is caused by an immune response to antigen inhalation and is characterized by progressive pulmonary fibrosis. The histopathological and clinical features of CHP are variable, however, a subset of CHP patients have usual interstitial pneumonia and behave clinically similar to patients with idiopathic pulmonary fibrosis (IPF). To determine the common and unique molecular features of CHP and IPF, we conducted a transcriptome analysis of lung samples from CHP (N=82), IPF (N=103), and unaffected controls (N=103). \u0000 \u0000Methods: Gene expression in lung tissue was determined adjusting for sex, race, age, explant site, and smoking history, and using false discovery rate (FDR) to control for multiple comparisons. \u0000 \u0000Findings: When compared to controls, we identified 413 upregulated and 317 downregulated genes in CHP, and 861 upregulated and 322 downregulated genes in IPF. Concordantly up/down-regulated genes in CHP and IPF were related to collagen catabolic processes and epithelial development, whereas genes specific to CHP were related to chemokine-mediated signaling and immune responsiveness. Using weighted gene co-expression network analysis (WGCNA), we found that among subjects with CHP, genes involved in adaptive immunity or epithelial cell development were associated with improved or reduced lung function respectively, and that MUC5B expression was associated with epithelial cell development. MUC5B expression was also associated with lung fibrosis and honeycombing. \u0000 \u0000Interpretation: Gene expression analysis of CHP and IPF identified signatures common to CHP and IPF, as well as genes uniquely expressed in CHP. Select modules of gene expression are characterized by distinct clinical and pathological features of CHP. \u0000 \u0000Funding Statement: NHLBI (R01-HL097163, P01-HL092870, UH3-HL123442, and DoD W81XWH17-1-0597). \u0000 \u0000Declaration of Interests: None of the authors report conflicts of interest relevant to this study. D.A.S. is the founder and chief scientific officer of Eleven P15, a company focused on the early diagnosis and treatment of pulmonary fibrosis. D.A.S. has an awarded patent (US patent no: 8,673,565) for the treatment and diagnosis of fibrotic lung disease. \u0000 \u0000Ethics Approval Statement: This study conformed to the Declaration of Helsinki and was approved by the Colorado Multiple Institution Board (COMIRB) 15-1147.","PeriodicalId":296065,"journal":{"name":"D56. ENVIRONMENTAL INTERSTITIAL LUNG DISEASE","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126738689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}